This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Disorders of intestinal carbohydrate absorption탄수화물흡수의 장애

Contents and key points
ItemDetails
A. Classification codesICD-10: E74.3 (disorders of intestinal carbohydrate absorption) | Special Copayment Reduction: V286 (severe intractable disease, 5 years)
B. SynonymsSucrase deficiency (sucrase-isomaltase deficiency, SID), other disorders of intestinal carbohydrate absorption, glucose-galactose malabsorption (GGM), congenital lactase deficiency, congenital sucrase-isomaltase deficiency (CSID)
C. Adult onsetLikelihood of adult onset: moderate — GGM and congenital lactase deficiency present in the neonatal period, but CSID is sometimes first diagnosed in adulthood depending on symptom severity. In adults as well, symptoms persist with poor dietary control.
1. History1960s: sucrase-isomaltase deficiency described → 1962: GGM first reported by Anderson → SLC5A1 (SGLT1) gene cloned (1987) → SI gene variants identified (1990s).
2. CausesCSID: biallelic SI gene variants; GGM: SLC5A1 gene (SGLT1) variants; congenital lactase deficiency: abnormal early expression of the LCT gene.
3. GeneticsSI (3q25.2) autosomal recessive/incomplete dominant; SLC5A1 (22q13.1) autosomal recessive; LCT (2q21.3) autosomal recessive.
4. General epidemiologyCSID prevalence 1:500 (Inuit) to 1:5,000 (Europe); GGM very rare (about 300 cases); adult (acquired) lactose intolerance about 65% worldwide.
5. PathophysiologyDeficiency of enzymes that break down and absorb disaccharides and monosaccharides → accumulation of osmotic substances in the intestinal lumen → osmotic diarrhea; fermentation by intestinal bacteria → gas production.
6. SymptomsWatery osmotic diarrhea (acidic stool, pH <6), abdominal pain, abdominal distension, excessive gas, failure to thrive (infants), dehydration and electrolyte abnormalities in GGM.
7. SignsAcidic watery stool (pH <6, reducing sugar positive), abdominal distension, failure to thrive, dehydration, hypernatremia, and renal dysfunction in GGM.
8. ScreeningHydrogen breath test (measurement of hydrogen gas after sucrose/glucose loading); stool pH and reducing sugar test (newborn screening); genetic testing when suspected.
9. DiagnosisHydrogen breath test (sucrose loading); small intestinal biopsy + measurement of disaccharidase activity (diagnostic standard); SI and SLC5A1 gene testing; in GGM, normal blood glucose response after intravenous glucose.
10. TreatmentCSID: sucrase enzyme replacement (sacrosidase); dietary restriction of sucrose and isomaltose; GGM: complete elimination of glucose and galactose + fructose-based formula.
11. PrognosisCSID: good with dietary restriction and enzyme therapy; GGM: infant survival is possible with strict dietary management but lifelong management is needed; congenital lactase deficiency: good with avoidance of dairy products.
12. PreventionEarly diagnosis by genetic testing when there is a family history; avoidance of diets containing the causative disaccharide; immediate formula change in infants with GGM.
13. ReferencesTreem WR. J Pediatr Gastroenterol Nutr 1995 and 9 other papers

1. History

The history of intestinal carbohydrate malabsorption begins with the discovery of small intestinal mucosal enzymes and the description of clinical syndromes caused by their deficiency. In 1960, Auricchio et al. confirmed that sucrase-isomaltase (SI) enzyme activity is located at the brush border of the small intestinal mucosa, and in the same year Weijers and van de Kamer first described SI enzyme deficiency in children with chronic diarrhea after sucrose ingestion. This disease was named congenital sucrase-isomaltase deficiency (CSID).

Glucose-galactose malabsorption (GGM) was described in 1962 when Anderson and di Sant'Agnese first reported a newborn who developed fatal watery diarrhea with every feeding containing glucose or galactose from just after birth. It was the 1966 study of Meeuwisse and Dahlqvist that biochemically established that this disease is due to a defect of the sodium-glucose cotransporter (SGLT1) in the small intestinal mucosa. The SLC5A1 gene encoding SGLT1 was cloned in 1987 by Hediger et al.

The genetic basis of CSID was elucidated in the 1990s. Variants in the SI gene were confirmed to be directly associated with CSID, and the high prevalence (about 1:500) found in North American Inuit native people drew attention. This is explained as the result of specific founder variants (c.273_274insC, p.F2Y, etc.) accumulating at high frequency in this population. Since the 2000s, it has been proposed that SI variants show incomplete dominance, so that heterozygous carriers can also show mild symptoms of sucrose intolerance.

In terms of treatment, in 1998 the US FDA approved a yeast-derived sucrase enzyme preparation (sacrosidase, Sucraid) for the treatment of CSID, making an alternative or adjunct to strict dietary sucrose restriction possible. For GGM treatment, immediate switch to a fructose-based formula remains the only method.


2. Causes

The major carbohydrate absorption disorders included in ICD-10 E74.3 are as follows.

Congenital sucrase-isomaltase deficiency (CSID)

Biallelic or incompletely dominant loss-of-function variants in the SI (sucrase-isomaltase) gene (3q25.2) reduce sucrase and isomaltase activity at the small intestinal brush border. Sucrose and isomaltose, a digestion product of starch, cannot be broken down into monosaccharides, causing osmotic diarrhea. Because heterozygous carriers can also show mild sucrose intolerance (incomplete dominance), there is also the view that the prevalence of CSID may be much higher than previously estimated.

Glucose-galactose malabsorption (GGM)

Biallelic loss-of-function variants in the SLC5A1 gene (22q13.1) cause loss of function of SGLT1 (sodium-glucose cotransporter type 1) in the small intestinal mucosa, completely blocking absorption of glucose and galactose. It is a neonatal emergency in which fatal watery diarrhea occurs immediately when breast milk or ordinary formula is fed just after birth. Because fructose is absorbed through GLUT5 rather than SGLT1, diarrhea stops immediately on switching to a fructose-based formula.

Congenital lactase deficiency

It is due to loss-of-function variants in the LCT (lactase-phlorizin hydrolase) gene and is a very rare disease (to be distinguished from acquired lactose intolerance). Watery diarrhea occurs from the neonatal period with breast milk or ordinary formula (containing lactose). Adult lactose intolerance is mostly due to a genetic polymorphism that reduces LCT gene expression after childhood (LCT -13910 C/C genotype, etc.; separate ICD-10 code), which is distinguished from the congenital deficiency of E74.3.


3. Genetics

The SI gene is located on chromosome 3 (3q25.2-q26.2) and encodes the sucrase-isomaltase precursor protein, composed of 1827 amino acids. About 50 or more pathogenic variants have been reported to date, and specific variants (c.3120+5G>A, etc.) are present at high frequency in the Inuit population. In the general European population, variants such as p.Q117R and p.Q1098P have been reported, and a recent whole-genome analysis study found a high incidence of irritable bowel syndrome (IBS) in carriers of SI heterozygous variants, raising the possibility of underdiagnosis. The SLC5A1 gene is located on chromosome 22 (22q13.1) and encodes SGLT1 of 664 amino acids. In GGM it is mostly expressed as homozygous or compound heterozygous variants. About 40 variants have been reported to be associated with GGM to date. GGM is very rare, with fewer than 300 patients worldwide. The LCT gene is located on chromosome 2 (2q21.3), and the number of variants in congenital lactase deficiency is very small. The LCT -13910 T>C polymorphism (rs4988235), the cause of acquired lactose intolerance, is associated with lactase persistence in northern European populations.


4. General epidemiology

The prevalence of CSID differs greatly between populations. It is particularly high, about 1:500 (0.2%) in Inuit native people of Canada and Alaska and 1:25 (4%) in Greenland Inuit. In the general European population it is 1:1,000–1:5,000, and in non-native North American populations it is estimated at 1:2,000–1:5,000. From the standpoint that SI gene heterozygous variants may be associated with IBS-related symptoms, the true prevalence may be much higher. GGM is a very rare disease with about 300 case reports worldwide. It is reported relatively more often in Finnish and some Middle Eastern populations. Congenital lactase deficiency shows its highest prevalence in Finland (Finnish disease heritage), but is very rare worldwide.


5. Pathophysiology

Mechanism of CSID: Sucrose (sucrose = glucose + fructose) cannot be broken down into glucose and fructose by sucrase at the small intestinal mucosal brush border, and isomaltose (an intermediate product of starch digestion) cannot be broken down into glucose by isomaltase. Undigested sucrose and isomaltose raise osmotic pressure in the small intestinal lumen, drawing water into the intestinal lumen (osmotic diarrhea), and on reaching the colon they are fermented by intestinal bacteria into short-chain fatty acids, carbon dioxide, and hydrogen gas, causing abdominal distension, flatulence, and acidification of the stool.

Mechanism of GGM: SGLT1 (Na⁺/glucose cotransporter 1) at the small intestinal brush border normally absorbs glucose and galactose into intestinal mucosal cells together with Na⁺. When SGLT1 function is lost, glucose and galactose cannot be absorbed and accumulate in the intestinal lumen, causing severe osmotic diarrhea. At the same time, without Na⁺-glucose cotransport, Na⁺ is retained in the intestinal lumen, causing electrolyte abnormalities and dehydration. Fructose is absorbed Na⁺-independently via GLUT5 (SLC2A5), so it is absorbed normally in GGM.


6. Symptoms

CSID: After the start of weaning foods, watery osmotic diarrhea, abdominal pain, abdominal distension, and excessive flatulence occur after eating foods containing sucrose or starch. Stool pH is low (acidic, <6) and reducing sugar is positive. During breastfeeding there is no sucrose and so no symptoms, and the disease first appears after the introduction of weaning foods (fruits, vegetables, starches). Growth and development may be delayed. In adults as well, mild sucrose intolerance can be mistaken for irritable bowel syndrome (IBS-D), and it is sometimes first diagnosed in adulthood. GGM: Immediately after the first feeding of breast milk or ordinary formula (containing glucose, galactose, and lactose) after birth, severe watery diarrhea, dehydration, hypernatremia, and metabolic acidosis occur. Without immediate treatment, it can lead to renal failure from dehydration, brain damage, and death. Diarrhea stops immediately on switching to a fructose-based formula. Congenital lactase deficiency: With breast milk or ordinary formula (containing lactose) after birth, severe osmotic diarrhea, dehydration, and abdominal pain occur. Symptoms are fully controlled with avoidance of dairy products and lactose-free formula.


7. Signs

On stool testing, acidic reaction (pH <6) and positive reducing sugar are characteristic (Clinitest or Benedict reagent). An elevated stool osmotic gap confirms the osmotic mechanism. In GGM, dehydration (decreased skin turgor, dry mucous membranes, no tears), hypernatremia, metabolic acidosis, and renal dysfunction are confirmed on physical and laboratory findings. In CSID, abdominal distension is clearly observed on physical examination and bowel sounds are increased. Failure to thrive (weight and height at low percentiles) results from chronic carbohydrate malabsorption. On small intestinal biopsy histology, the villi and mucosal architecture are generally normal (non-infiltrative), but brush border enzyme activity is markedly reduced.


8. Screening

Screening of the general population is not performed. In newborns with osmotic diarrhea, immediate testing of stool pH and reducing sugar is the initial screening for GGM and congenital lactase deficiency. In patients suspected of CSID, a sucrose hydrogen breath test is performed: sucrose 2 g/kg (maximum 50 g) is given orally and breath hydrogen concentration is measured for 30 minutes to 3 hours. In healthy individuals, sucrose is completely absorbed in the small intestine and no hydrogen gas is produced, whereas in CSID patients hydrogen rises sharply from bacterial fermentation in the colon (positive criterion: a rise of 20 ppm or more over baseline). When there is a family history, SI or SLC5A1 gene testing is performed.


9. Diagnosis

The standard for diagnosing CSID is measurement of disaccharidase activity in small intestinal biopsy tissue (duodenal or jejunal mucosa). Sucrase activity is markedly reduced (<20% of normal) and isomaltase activity is also decreased. Lactase activity is generally normal. Genetic variant analysis is a noninvasive diagnostic method, performed as full sequencing of the SI gene or testing of a panel of known variants. The sucrose breath test is a noninvasive method with a sensitivity of about 80–90%. Diagnosis of GGM: in newborns, blood glucose rises normally with intravenous glucose but intestinal malabsorption is confirmed on oral glucose loading. SLC5A1 gene variant analysis is the confirmatory method. Stool pH (<6), positive reducing sugar, and immediate resolution of diarrhea when glucose-based formula is stopped provide clinical diagnostic clues. Resolution of symptoms after switching to a fructose-based formula strongly supports GGM.


10. Treatment

CSID: Enzyme replacement therapy is available. Sacrosidase (Sucraid) is an invertase preparation derived from Saccharomyces cerevisiae (yeast); taken orally with meals, it breaks down sucrose in the small intestine and prevents diarrhea. It is the only CSID treatment enzyme, approved by the FDA in 1998. When enzyme therapy is not possible or is insufficient, foods containing sucrose, isomaltose, and starch (a source of isomaltose) are restricted. Depending on individual tolerance, some starches (such as rice) may be allowed. GGM: Immediate elimination of glucose and galactose is the only life-saving treatment. Switch immediately to a fructose-based formula (e.g., Vivonex, Tolerex, or a formula containing fructose alone). With growth, some patients may develop tolerance to small amounts of glucose, but most require lifelong restriction of glucose and galactose. Dehydration and electrolyte abnormalities are corrected with intravenous fluids. Congenital lactase deficiency: a diet completely free of dairy products and lactose (using lactose-free formula or soy-based formula).


11. Prognosis

In CSID, symptoms can be controlled and growth and development normalize with adherence to dietary modification and enzyme therapy. Symptoms can recur in adulthood when sucrose is ingested, so lifelong management is needed. Sacrosidase is well tolerated with long-term use, and serious adverse effects other than allergic reactions (yeast hypersensitivity) are rare. The prognosis of GGM varies greatly with the degree of dietary management adherence. If glucose and galactose are eliminated immediately and adequate nutrition is provided, growth and development can normalize. However, if diagnosis is delayed or dehydration and electrolyte abnormalities recur, neurological damage, growth retardation, and renal dysfunction may remain. Congenital lactase deficiency can be fully controlled by avoiding dairy products and has an excellent prognosis.


12. Prevention

When there is a family history (a confirmed parent or an affected sibling), early diagnosis by genetic testing is important. If a CSID patient is diagnosed before weaning foods are started, the introduction of sucrose-containing weaning foods can be delayed or replaced with sucrose-free weaning foods. In GGM patients, avoiding glucose- and galactose-based feeding immediately after birth and starting a fructose-based formula immediately saves lives. Prenatal genetic diagnosis should be considered at the next pregnancy in GGM families. CSID patients must avoid sucrose-containing foods and intravenous fluids when eating out, being hospitalized, or having surgery (glucose fluids are acceptable, but caution with sorbitol-containing nutritional products). Check all food labels carefully and carry sacrosidase enzyme preparations at all times.


13. References

  1. Treem WR. Congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1995;21(1):1-14. DOI: 10.1097/00005176-199507000-00001. PMID: 7563420.
  2. Rhoads JM, Bhutani V, Cooke RJ, et al. Glucose-galactose malabsorption. J Pediatr. 1989;114(4):558-562. DOI: 10.1016/s0022-3476(89)80694-3. PMID: 2926541.
  3. Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987;330(6146):379-381. DOI: 10.1038/330379a0. PMID: 2825027.
  4. Naim HY, Roth J, Sterchi EE, Lentze M, et al. Sucrase-isomaltase deficiency in humans: different mutations disrupt intracellular transport, processing, and function of an intestinal brush border enzyme. J Clin Invest. 1988;82(2):667-679. DOI: 10.1172/JCI113643. PMID: 3047153.
  5. Karnsakul W, Luginbuehl U, Hahn D, et al. Disaccharidase activities in dyspeptic children: biochemical and molecular investigations of sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 2002;35(4):551-556. DOI: 10.1097/00005176-200210000-00018. PMID: 12394383.
  6. Leis R, Tojo R, Pavon P, Dalmau J. Prevalence of lactose malabsorption in Galicia. J Pediatr Gastroenterol Nutr. 1997;25(3):296-300. PMID: 9285380.
  7. Martin MG, Turk E, Lostao MP, Kerner C, Wright EM. Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet. 1996;12(2):216-220. DOI: 10.1038/ng0296-216. PMID: 8563765.
  8. Husein S, Shen D, Moore EA, Grewal AK, Naim HY. Sucrase-isomaltase deficiency from molecule to disease. Clin Transl Gastroenterol. 2021;12(9):e00397. DOI: 10.14309/ctg.0000000000000397. PMID: 34550945.
  9. Cohen SA. The clinical consequences of sucrase-isomaltase deficiency. Mol Cell Pediatr. 2016;3(1):5. DOI: 10.1186/s40348-016-0033-7. PMID: 26879862.
  10. Diekmann L, Pfeiffer K, Naim HY. Congenital sucrase-isomaltase deficiency: heterogeneity of inheritance, trafficking, and function of an intestinal enzyme complex. J Pediatr Gastroenterol Nutr. 2015;60(5):580-586. DOI: 10.1097/MPG.0000000000000702. PMID: 25707966.